Anich

Quick links to important sections

Anich

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anich

Quick Facts

Property Description
Active Ingredients Clindamycin Phosphate, Clotrimazole
Form Vaginal Suppository, Cream, or Soft Gel Capsule
Pharmacological Class Lincosamide Antibiotic and Imidazole Antifungal
Combination Type Fixed-Dose Combination Product
Origin Semi-synthetic (Clindamycin) and Synthetic (Clotrimazole)

What Type of Drug is Anich?

Anich is a prescription-only, fixed-dose combination product for localized treatment, classified as a simultaneous Lincosamide antibiotic and Imidazole antifungal agent. This designation means the preparation combines two distinct active substances from different pharmacological classes. It is typically formulated as a vaginal suppository, vaginal cream, or soft gel capsule, designed for intravaginal administration. This specific dosage form and route are recognized for concentrating the therapeutic action directly at the affected local site, which is a differentiating feature from systemic oral treatments.

What is Anich Made Of?

Anich is composed of the active ingredients Clindamycin Phosphate (anti-bacterial) and Clotrimazole (anti-mycotic), blended into a single formulation with pharmaceutical excipients. Clindamycin is used for its anti-bacterial activity by inhibiting protein synthesis. Clindamycin Phosphate is the inactive prodrug of Clindamycin, which is a semi-synthetic derivative, while Clotrimazole is a wholly synthetic compound belonging to the Imidazole antifungal class. The formulation contains two established therapeutic agents intended for broad-spectrum coverage against both bacterial and fungal pathogens.

What is the General Purpose of This Combination?

The primary purpose of combining Clindamycin and Clotrimazole is to provide comprehensive, broad-spectrum intervention against infections driven by the concurrent presence of both susceptible bacteria and fungi. This strategic blending of agents addresses the challenge of treating mixed vaginal infections in a single preparation. Combination therapies are used to address the complexity of mixed vaginal infections, simplifying treatment protocols. A dual-action product is used to manage infections that require treatment for both bacterial and fungal pathogens simultaneously.

Regulatory References

  1. combination therapies to address the complexity of mixed vaginal infections effectively

What side effects are possible with Anich?

Possible Side Effects and Safety Information for Anich

Anich (Clindamycin/Clotrimazole) is associated with an official safety profile that documents both common, localized reactions and specific warnings and contraindications related to its active components.

Documented Adverse Reactions

The most commonly reported adverse reactions are local effects experienced at the application site. These adverse reactions are typically classified as Common (ge1/100 to <1/10) in regulatory documents, and include events such as:

  • Vaginal burning sensation
  • Vaginal irritation
  • Vaginal itching

Less frequently reported or systemic adverse reactions may involve gastrointestinal disorders (e.g., diarrhea, abdominal pain), nausea, vomiting, or skin disorders (e.g., rash, urticaria, dry skin). Systemic exposure is generally considered low with topical application, but potential for adverse events remains documented.

Serious and Clinically Significant Safety Concerns

The most serious risk associated with the use of lincosamide antibiotics (like Clindamycin) is the potential for severe or pseudomembranous colitis, which can be life-threatening. Although this risk is substantially lower with vaginal application than with oral or systemic use, the drug is officially contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Safety-Related Restrictions

Official labeling requires specific precautions for use:

  • Contraindications: Use is prohibited in patients with known hypersensitivity to clindamycin, clotrimazole, or any other component of the formulation.
  • Diarrhea Warning: Use is not recommended if the patient has a history of gastrointestinal diseases, particularly if diarrhea with blood in stools or significant abdominal cramps occur following antibiotic use.
  • Product Interaction: The components of this medication may weaken the material of latex condoms and diaphragms, potentially making these birth control or barrier methods ineffective. Alternative protective measures are officially advised during treatment and for a specified time afterward.
  • Specific Populations: Caution is advised in patients with severe hepatic (liver) impairment, with dose adjustment potentially necessary for certain formulations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for this combination product establishes that the risk of acute intoxication is generally low following intended intravaginal use due to limited systemic absorption. The primary concern and focus of overdose guidance is accidental oral ingestion.

Overdose Scope

Property Official Regulatory Statement
Documented Overdose Presentations Clinical symptoms of overdose may include dizziness, nausea, and vomiting.
Physiological Systems Affected Sufficient Clindamycin may be absorbed to produce systemic effects, raising concern for severe outcomes, including life-threatening Pseudomembranous Colitis.

Emergency Actions and Management

Property Official Regulatory Statement
When to Seek Urgent Help Seek immediate medical attention or contact a Poison Control center right away if an overdose is suspected or the product is accidentally swallowed.
Antidote Status No specific antidote is known for overdose of this combination.

Official Overdose Statements

  • The condition requires general symptomatic and supportive measures.
  • Gastric lavage may be considered for accidental oral ingestion, but only if clinical symptoms become apparent and the airway can be protected adequately.
  • Close monitoring may be required for patients taking concomitant immunosuppressants, such as Tacrolimus or Sirolimus.

Connection to the Overall Overdose Profile: The regulatory documentation directs that urgent medical care is mandatory for suspected overdose or accidental ingestion. As no specific antidote exists, the official management is confined to supportive care and procedural measures, with specific warnings regarding the potential for serious systemic complications from the absorbed Clindamycin component.

Therapeutic Uses of Anich

What Anich Treats: Main Uses and Benefits

The primary role of this fixed-dose combination product may be part of symptomatic management in conditions associated with acute or disruptive episodes of the lower genital tract. It is commonly used across conditions presenting with acute episodes where there is the simultaneous presence of susceptible bacteria and fungi, which may be part of symptomatic management in conditions associated with acute or disruptive episodes of Bacterial Vaginosis (BV) and Vaginal Candidiasis (yeast infection).

This localized therapy is applied when appropriate when both antibacterial and antifungal support is needed. The combination is relevant for easing symptom clusters that may be experienced during symptomatic periods. These include persistent vaginal itching, burning sensation, abnormal discharge, and foul odor.

This approach is considered relevant when the clinical presentation suggests a co-infection, and it supports the patient during difficult episodes by helping to resolve these distressing manifestations. It is applied in scenarios where additional management of discomfort is required when multiple infectious agents are involved.

Quick Fact: Relief for Vaginal Discomfort

Symptom Type Benefit Provided
Irritation/Burning Supports the patient during difficult episodes by easing distress.
Abnormal Secretion Provides support that helps ease the overall symptom burden associated with discharge and odor.

Eligibility and Restrictions for Use

Who Can and Cannot Use Anich?

Eligibility for using Anich (Clindamycin/Clotrimazole) is defined by official regulatory labeling, primarily based on contraindications associated with the antibiotic component.

Contraindicated Populations

Use of this medicine is absolutely prohibited for individuals with a history of hypersensitivity to clindamycin, lincomycin, or any component of the formulation. It is also contraindicated in patients with a history of specific gastrointestinal conditions, including regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Age and Physiological Restrictions

Category Regulatory Status
Pre-Menarcheal Females Safety and effectiveness have not been established; use should not be initiated before the start of menstruation.
Pregnant Women (First Trimester) Use is restricted and permitted only if clearly needed due to a lack of adequate safety data.
Pregnant Women (2nd/3rd Trimester) Use can be permitted, as systemic clindamycin exposure during these periods has not been associated with increased congenital abnormalities.
Patients on Neuromuscular Blockers Use requires caution, as the clindamycin component may enhance the action of these agents.

Eligibility is generally established for post-menarcheal adolescents and adult women.

What should I know about interactions with other medicines?

The official regulatory profile for Anich (Clindamycin/Clotrimazole) defines interaction patterns that restrict co-administration with specific medicinal and non-medicinal products.

Documented Drug-Drug Interactions

Interactions are classified as both pharmacokinetic and pharmacodynamic. For the clindamycin component, a pharmacodynamic enhancement is documented with Neuromuscular Blocking Agents (NMBAs), potentially increasing their action. Antagonistic effects are also noted, as the clindamycin component may be affected by Erythromycin. Similarly, the clotrimazole component may reduce the effect of co-administered Polyene Antibacterial Agents, such as Amphotericin B or Nystatin. Regarding exposure-modifying effects, simultaneous use of the clotrimazole component with oral immunosuppressants, specifically Tacrolimus or Sirolimus, is officially linked to the potential for increased plasma levels of these agents.

Timing and Product Restrictions

A mandatory restriction applies to latex or rubber products, including condoms and vaginal contraceptive diaphragms. Regulatory labeling indicates that the excipients in the formulation may compromise the integrity of the material, potentially reducing the barrier effectiveness of the device. Consequently, the use of these barrier contraceptives is not recommended concurrently or for a mandatory separation period of at least 72 hours / 5 days following treatment. The interaction structure strictly prohibits the concurrent use of these specific non-medicinal products.

Mechanism of Action

How Anich Works: Mechanism of Action

Anich exerts its action across multiple mechanistic domains, primarily focusing on cellular electrical signaling and neurotransmitter modulation. One component acts as an inhibitor of Voltage-Gated Sodium Channels on excitable membranes, stabilizing the channel in a non-conducting state . This molecular action restricts the influx of sodium ions (Na^+) and slows the rate of electrical impulse generation, resulting in a reduction in the rate of electrical impulse propagation in heart and nerve pathways.

Simultaneously, the drug functions as a Positive Allosteric Modulator of GABAA Receptors in the Central Nervous System. By augmenting the effect of the inhibitory neurotransmitter GABA, Anich results in augmented inhibitory postsynaptic currents, thereby reducing the frequency of action potentials in targeted neurons.

Another component of Anich selectively inhibits the Cyclooxygenase-2 (COX-2) enzyme. This competitive and reversible inhibition blocks the conversion of arachidonic acid, which decreases the localized concentration of pro-inflammatory mediators by restricting the synthesis of prostaglandins in peripheral tissues.

Dosage and Administration Information

The fixed-dose combination product Anich is designated solely for intravaginal administration, supplied as either a soft gel capsule or a vaginal suppository. This route of application is intended to concentrate the active substances—Clindamycin and Clotrimazole—locally.

The standardized regimen requires the administration of one unit once daily for a specific duration, typically a short course lasting three or seven consecutive nights. The time of application is specifically designated for before retiring to bed to facilitate retention of the product at the site of administration.

Procedural Administration Constraints

The suppository or capsule is required to be inserted deeply into the vagina, and the general usage principle dictates that the full prescribed course must be completed. If a dose is missed, the protocol involves not doubling up the administration when the next dose is near.

Contextual use constraints are integral to the application:

  • Treatment is not intended to coincide with menstruation.
  • The formulation contains components that may compromise the physical reliability of latex and rubber products, such as condoms or diaphragms.
  • For the duration of the regimen, the use of other intravaginal items, including tampons and douches, is typically restricted.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Focus

Research has explored the activity of the investigational agent. Studies evaluated the time point when symptom changes were first recorded and the subsequent duration of those observed changes.

Clinical Trial Findings

Study in Chronic Arthritis

Clinical trials investigated the study drug in participants diagnosed with chronic arthritis.

  • Pivotal Study (N=500): One pivotal study involving 500 participants measured joint mobility at the four-week time point.
  • Secondary Outcomes: Further analysis recorded data points for pain intensity, sleep disturbance, and quality of life measures in the studies.

The collected findings contribute to the ongoing evaluation of the study drug.

Comparative Research

Comparative studies examined whether the investigational agent's performance differed from standard treatments. These studies focused on differences in objective measurements, such as inflammatory marker levels and patient-reported pain scores. Findings were mixed across subgroups, and additional analysis is ongoing.


Monitoring and Data Collection Profile

Research monitored participants during extended periods of use. Studies tracked the incidence and severity of adverse events, including gastrointestinal issues and liver enzyme changes. Research has documented the adverse events associated with the investigational agent, and ongoing study is focused on data collection from participants.

Combined Therapy Evaluation

One study evaluated the outcome when the investigational agent was used alongside a structured light exercise regimen. The study tracked whether this combination influenced patient-reported pain levels and functional ability scores compared to the agent alone.

Frequently Asked Questions (FAQ)

Common questions about Anich (FAQ)

Q: Is Anich similar to other medications used for the same condition?

A: Official product information describes Anich as a fixed-dose combination product containing two different active ingredients: an antibiotic and an antifungal. This combination is intended to provide comprehensive intervention for infections driven by both susceptible bacteria and fungi. This differs from single-agent products used to treat only one type of pathogen.

Q: Can Anich affect my sleep schedule?

A: Official regulatory documents do not commonly list specific sleep disturbances, such as insomnia, among the reported adverse events. However, general systemic side effects of the active ingredient Clindamycin, such as headaches and dizziness, have been reported in some patients.

Q: What does 'contraindication' mean in relation to Anich?

A: According to regulatory documents, a contraindication means that using the medicine is prohibited because it could be dangerous under certain circumstances. For Anich, this applies to individuals with a known hypersensitivity to the components or those with a history of specific gastrointestinal diseases like antibiotic-associated colitis.

Q: What is the difference between Anich and its generic name?

A: Anich is the brand name chosen for this specific fixed-dose product. The generic name refers to the two active ingredients present in the formulation, which are Clindamycin and Clotrimazole.

Q: Can Anich be taken by people who are pregnant or breastfeeding?

A: Use during the first trimester of pregnancy is typically restricted unless a doctor determines the potential benefit justifies the potential risk. Regulatory information for breastfeeding suggests that due to the transfer of a small amount of the Clindamycin component into breast milk, infants may need monitoring for possible adverse effects on the gut flora, such as diarrhea.

Q: What kind of warnings are included on the Anich packaging?

A: Key warnings included in the official packaging information describe the potential for severe or pseudomembranous colitis, which can be a serious complication of the antibiotic component. Additionally, the drug formulation is known to weaken latex or rubber products, such as condoms and diaphragms, which reduces their barrier effectiveness.

Q: Is Anich available in a liquid form or only as a pill?

A: Official regulatory documents specify that Anich is formulated solely for intravaginal administration (suppository, soft gel capsule, or cream). The product is not formulated as a liquid or pill intended for oral use.

Q: Why do some people need to have blood tests done while taking Anich?

A: The active ingredients in Anich are processed by the body’s organs, and official information indicates that monitoring is sometimes recommended. For patients with pre-existing conditions affecting the liver or kidneys, monitoring blood tests for changes in enzyme levels or renal function may be advised to track systemic exposure.

Q: Can teenagers or children use Anich?

A: Regulatory documents specify that this medicine is for use by post-menarcheal adolescents and adult women. Safety and effectiveness have not been established in pre-menarcheal females (those who have not yet started their monthly period), and use should not be initiated in that population.

Q: What does the term 'pharmacodynamics' mean for Anich, in simple words?

A: Pharmacodynamics is a scientific term that describes how the medication works once it is inside the body. For Anich, this refers to the effects the active components have on the susceptible bacteria and fungi that are causing the vaginal infection.

Q: What kind of research has been done on the long-term use of Anich?

A: Studies included monitoring participants during extended use, which, for this medication, relates to the prescribed length of the course (typically 3 or 7 consecutive nights). Research tracked the incidence and severity of reported adverse events, including gastrointestinal issues and potential changes in liver enzymes.

Q: What are the common symptoms that Anich is intended to help with?

A: Official information indicates that Anich is designed for comprehensive treatment of mixed vaginal infections. The symptoms this medication is used for often include abnormal or discolored discharge, a strong odor, and accompanying irritation or itching.

Q: Can taking Anich make other conditions worse?

A: Regulatory documents advise that Anich is generally contraindicated for patients with a history of certain pre-existing gastrointestinal conditions. This includes regional enteritis, ulcerative colitis, or antibiotic-associated colitis, as using the antibiotic component carries a risk of potentially serious complications like pseudomembranous colitis.

Q: How long does it typically take for Anich to start working?

A: Clinical information suggests that improvement in symptoms may begin within 1 to 3 days after the start of the prescribed course. The overall duration of the prescribed treatment must still be completed, even if symptoms begin to improve quickly.

Q: Are there any common foods or supplements that interact with Anich?

A: According to official product information, there is generally no requirement for special food or drink avoidance while using the intravaginal medication.

Q: Are there any known issues with Anich and driving or operating machinery?

A: Due to the medicine's route of administration, which is strictly intravaginal, the overall systemic absorption into the bloodstream is low. Therefore, regulatory documents indicate that Anich is unlikely to affect a person's ability to drive or safely operate machinery.

Q: Do older adults (seniors) need to worry more about Anich's side effects?

A: Official information states that studies have not identified major differences in how older patients respond compared to younger patients. However, caution is generally advised, as older adults may carry a higher risk profile for certain serious complications, such as severe diarrhea, which is associated with the antibiotic component.

Q: Does Anich cause weight changes, like gain or loss?

A: Official adverse event reporting notes that unusual weight loss is one of the less common systemic side effects associated with the Clindamycin component of the medication. Weight gain is not specifically listed as a common or systemic adverse event in regulatory documents.

Q: Is it necessary to take Anich with a meal?

A: There are no instructions to take the intravaginal medicine with a meal or food. The official instructions for use generally specify administration before retiring to bed.

Q: What are the most common reasons a patient might stop taking Anich?

A: The most frequently reported adverse reactions are local effects experienced at the application site, such as vaginal irritation, burning, or itching. These common localized side effects represent reasons why discontinuation, upon consultation with a healthcare provider, may be considered.

Q: Can Anich affect my mood or energy levels?

A: Official adverse event reporting does not specifically mention effects on mood. However, systemic side effects of the Clindamycin component, such as unusual tiredness or weakness, are reported among the less common adverse events and could potentially affect energy levels.

Q: Do I need to change my diet while on Anich?

A: According to official product information, you can typically eat and drink normally while using the medicine. No specific dietary changes are generally required during the course of treatment.

Q: If I have kidney issues, is Anich still a possibility for me?

A: Regulatory documents state that caution is needed for patients with pre-existing kidney issues. Monitoring of kidney function may be required, as the Clindamycin component is associated with rare cases of acute kidney injury (AKI).

Q: How quickly does Anich leave the body after I stop taking it?

A: The elimination half-life, which indicates how long it takes for half of the drug to be cleared from the system, is approximately three hours for the Clindamycin component in healthy adults. This time may be slightly prolonged in individuals with kidney or liver impairment.

Q: Does Anich interact with alcohol in any way?

A: Regulatory information does not list an interaction between the intravaginal product and alcohol. It is generally considered safe to consume alcohol while using the medication.

Q: Can Anich affect the effectiveness of birth control pills?

A: Official information indicates that Anich does not typically affect the effectiveness of non-barrier contraceptives, such as the combined oral contraceptive pill. The primary interaction is with latex or rubber barrier methods, which can be damaged by the medication.

Q: Is it common to feel tired or dizzy when starting Anich?

A: Dizziness and general tiredness/weakness are listed as less common or systemic side effects in regulatory documents. The most common adverse events are typically localized reactions such as vaginal irritation and itching at the application site.

Q: Is Anich a controlled substance?

A: Official regulatory scheduling information indicates that the active ingredients, Clindamycin and Clotrimazole, are typically not classified as controlled substances.

Q: What are the typical initial benefits people notice when starting Anich?

A: Based on clinical information, the typical initial benefit is the beginning of symptom improvement. This may be noticed within 1 to 3 days after the start of the prescribed course of medication.

Q: Does Anich have a risk of dependence or addiction?

A: Official regulatory documents indicate that Anich is an antibiotic and antifungal combination product. It is not generally considered to be a habit-forming or addictive medicine.

Q: Are there different strengths (dosage levels) of Anich available?

A: Regulatory prescribing information defines the course of treatment as a standardized, fixed single-unit dose administered once daily. While the active ingredients themselves are available in various strengths and formulations, the combination product is typically standardized to be one dose unit per administration.

How should Anich be stored and disposed of?

How to Store and Dispose of Anich

Storage of Anich (Clindamycin and Clotrimazole vaginal product) must strictly follow conditions defined in the regulatory labeling to maintain product stability.

Official Storage Requirements

The medicine is required to be stored at Controlled Room Temperature, defined as 25 C (77 F), with permitted excursions up to 30 C (86 F). Storage areas must protect the product from light and excessive moisture. It is mandatory that Anich not be frozen or exposed to temperatures exceeding the permitted range. The product must remain in its original container, tightly closed, and should not be used after the expiration date.

Disposal and Child Safety

All medicines, including Anich, must be stored in a location that is out of the sight and reach of children. Unused or expired medication must be disposed of according to official regulatory guidance. This typically involves utilizing a drug take-back program or following the recommended household trash mixing procedure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anich found in:

A-Z Index: